PropertyValue
?:abstract
  • A novel strain of coronavirus, namely, Corona Virus Infection Disease 19 has been identified in Wuhan city of China in December 2019, continues to spread at a rapid rate worldwide There are no specific therapies available and investigations regarding the treatment of this disease are still lacking In order to identify a novel potent inhibitor we performed docking studies on the main virus protease with eight drugs belonging to four pharmacological classes: anti-malarial, anti-bacterial, anti-infective and anti-histamine Among the eight studied compounds, Lymecycline and Mizolastine appear as potential inhibitors of this protease These two compounds revealed a minimum binding energy of -8 87 and -8 71 Kcal/mol with 168 and 256 binding modes detected in the binding substrate pocket, respectively Lymecycline and Mizolastine interact with specific residues in substrate binding cavity Thus, Lymecycline and Mizolastione may serve as a tool to fight COVID-19 disease However, this data need further in vitro and in vivo evaluation to repurpose these two drugs against COVID-19 disease
is ?:annotates of
?:creator
?:license
  • unk
?:publication_isRelatedTo_Disease
is ?:relation_isRelatedTo_publication of
?:source
  • WHO
?:title
  • Molecular Docking Study of COVID-19 Main Protease with Clinically Approved Drugs
?:type
?:who_covidence_id
  • #421
?:year
  • 2020

Metadata

Anon_0  
expand all